DelveInsight’s ‘Hepatocellular Carcinoma Pipeline Insight 2023’ report provides comprehensive global coverage of pipeline Hepatocellular Carcinoma therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Hepatocellular Carcinoma pipeline domain.

For Hepatocellular Carcinoma emerging drugs, the Hepatocellular Carcinoma pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

 

For further information on the Hepatocellular Carcinoma therapy in the pipeline, reach out @ Hepatocellular Carcinoma Medication

 

Key Takeaways from the Hepatocellular Carcinoma Pipeline Report

• DelveInsight’s Hepatocellular Carcinoma Pipeline analysis depicts a robust space with 90+ active players working to develop 95+ pipeline therapies for Hepatocellular Carcinoma treatment. 
• The leading Hepatocellular Carcinoma companies include Can-Fite BioPharma, Sinocelltech, AVEO Oncology, Oxford BioTherapeutics, Beijing SyngenTech, Surface Oncology, Novartis Oncology, Array BioPharma, Taizhou Hanzhong Pharmaceuticals, Akeso Biopharma, Shanghai Henlius Biotech, Chugai Pharmaceutical, CStone Pharmaceuticals, Shenogen Pharma, GlaxoSmithKline, Tarus Therapeutics, Tvardi Therapeutics, Virogin Biotech, Yiviva, Chia Tai Tianqing Pharmaceutical Group, Antengene Corporation, Iterion Therapeutics, Sumitomo Pharma, SillaJen Biotherapeutics, SCG Cell Therapy, Guangdong ProCapZoom Biosciences, Eutilex, Polaris Pharmaceuticals, OriCell Therapeutics, Gongwin Biopharm, Celgene Corporation, Phanes Therapeutics, MacroGenics, Genoscience Pharma, Tempest Therapeutics, JW Therapeutics, NETRIS Pharma, Adagene, and others are evaluating their lead assets to improve the Hepatocellular Carcinoma treatment landscape.
• Key Hepatocellular Carcinoma pipeline therapies in various stages of development include Namodenoson, Tivozanib, SCT-I10A, OBT-624, SynOV1.1, SRF388, INC280, HX008, AK104, Serplulimab, ERY974, Fisogatinib, Icaritin, TSR-022, TT-4, TTI-101, VG161, YIV-906, TQB2450, ATG 008, BBI608, Tegavivint, Pexastimogene Devacirepvec, SCG101, SZ003, EU307, ADI-PEG20, Ori-C101, Para-Toluenesulfonamide, CC-122, PT199, vobramitamab duocarmazine, ezurpimtrostat, TPST-1120, JWATM214, NP137, ADG126, and others.
• In July 2023, the FDA accepted for evaluation a new drug application seeking approval of rivoceranib in conjunction with camrelizumab as a first-line therapy option for patients with unresectable hepatocellular carcinoma (HCC).
• In July 2023, Can-Fite BioPharma Ltd., a biotechnology company developing a pipeline of proprietary small molecule drugs to treat oncology, inflammatory, and liver diseases, announced that its abstract titled “A novel approach for the treatment of advanced hepatocellular carcinoma (HCC)” was one of the highest scoring abstracts and received the prestigious Breakthrough Abstract Award from Conquer Cancer, the ASCO Foundation, and the 2023 ASCO Breakthrough Programme Committee.
• In May 2023, Harbour BioMed announced the results of the phase Ib clinical trial of porustobart (HBM4003), in combination of toripalimab in patients with hepatocellular carcinoma (HCC) (trial code: NCT05149027) were released at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023.
• In April 2023, Tempest Therapeutics announced positive early results from a global randomized Phase Ib/II clinical study in which TPST-1120, Tempest’s small molecule PPAR⍺ antagonist, demonstrated clinically-meaningful improvement in multiple categories when combined with the standard-of-care regimen of atezolizumab and bevacizumab in a randomized comparison to atezolizumab and bevacizumab in the first-line treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC).

 

Request a sample and discover the recent breakthroughs happening in the Hepatocellular Carcinoma pipeline landscape @ Hepatocellular Carcinoma Pipeline Outlook

 

Hepatocellular Carcinoma Overview

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, accounting for the majority of cases. It typically originates in hepatocytes, the main type of liver cells. HCC can have serious consequences, as it tends to progress rapidly and may spread to other parts of the body if not detected and treated early. Several factors can contribute to the development of hepatocellular carcinoma. Chronic viral infections, particularly hepatitis B and C, are considered major risk factors.

The symptoms of hepatocellular carcinoma can vary depending on the stage of the disease. In the early stages, individuals may experience no symptoms at all. As cancer progresses, common symptoms may include abdominal pain or discomfort, weight loss, loss of appetite, fatigue, jaundice (yellowing of the skin and eyes), abdominal swelling, and easy bruising or bleeding.

Diagnosing hepatocellular carcinoma typically involves a combination of imaging tests, blood tests, and a biopsy. Imaging tests such as ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI) can help visualize the liver and detect any suspicious masses. Blood tests may be done to assess liver function and check for specific markers that indicate HCC. If a suspicious mass is found, a biopsy may be performed to obtain a sample of the liver tissue for further analysis and confirmation of the diagnosis.

 

Find out more about Hepatocellular Carcinoma medication @ New Drug for Hepatocellular Carcinoma 

 

Hepatocellular Carcinoma Treatment Analysis: Drug Profile

Namodenoson: Can-Fite BioPharma

Namodenoson, also known as Cl-IB-MECA (2-chloro-N6-(3-iodobenzyl)-adenosine-5′- N-methyl-propanamide), is an oral small molecule medication that is a highly specific and selective agonist at the A3 adenosine receptor (A3AR). For treating liver cancer and NASH, the medication was out-licensed to Chong Kun Dang (CKD) Pharmaceutical in Korea and CMS in China. Phase I/II research in hepatocellular carcinoma (HCC) satisfied its primary and secondary goals, indicating early indications of Namodenoson efficacy. A global Phase II research using Namodenoson as a second-line treatment on patients was just completed. Although the primary aim of overall survival was not met, a significant clinical impact was seen in a subset of Child-Pugh B7 (CPB7) patients. The Company secured an agreement with the FDA and the EMA on a Phase III protocol in the CPB7 population during an End-of-Phase II conference. The medication is now in Phase III development for the treatment of Hepatocellular carcinoma.

SRF388: Surface Oncology

SRF388 is a fully human anti-IL-27 antibody that is intended to block the function of this immunosuppressive cytokine. IL-27 is an immunosuppressive cytokine that has a role in the resolution of T cell-mediated inflammation. Recent evidence suggests that IL-27 is a master regulator of the production of co-inhibitory receptors on CD4+ and CD8+ T cells. Cancer has elevated amounts of IL-27 transcripts and mRNA gene signatures, which are associated with a bad prognosis. Surface Oncology has discovered several tumor forms in which IL-27 appears to play a major function in the immunosuppressive tumor microenvironment and may lead to checkpoint inhibitor resistance. Surface Oncology has also identified a possible biomarker related to IL-27 that may be beneficial in identifying individuals who are most likely to respond to SRF388. The drug is currently in Phase II development for the treatment of Hepatocellular carcinoma.

 

Key Hepatocellular Carcinoma Therapies and Companies

• Namodenoson: Can-Fite BioPharma
• SCT-I10A: Sinocelltech
• SRF388: Surface Oncology
• Capmatinib: Novartis Oncology
• Fisogatinib: CStone Pharmaceuticals
• Tivozanib: AVEO Oncology
• ERY974: Chugai Pharmaceutical

 

Learn more about the novel and emerging Hepatocellular Carcinoma pipeline therapies @ Hepatocellular Carcinoma Clinical Trials

 

Hepatocellular Carcinoma Therapeutics Assessment

By Product Type

• Monotherapy
• Combination Therapy

 

By Stage

• Discovery
• Pre-Clinical
• Phase I
• Phase II
• Phase III
• Pre-registration

 

By Route of Administration

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

 

By Molecule Type

• Oligonucleotide
• Peptide
• Small molecule

 

Scope of the Hepatocellular Carcinoma Pipeline Report 

• Coverage: Global 
• Key Hepatocellular Carcinoma Companies: Can-Fite BioPharma, Sinocelltech, AVEO Oncology, Oxford BioTherapeutics, Beijing SyngenTech, Surface Oncology, Novartis Oncology, Array BioPharma, Taizhou Hanzhong Pharmaceuticals, Akeso Biopharma, Shanghai Henlius Biotech, Chugai Pharmaceutical, CStone Pharmaceuticals, Shenogen Pharma, GlaxoSmithKline, Tarus Therapeutics, Tvardi Therapeutics, Virogin Biotech, Yiviva, Chia Tai Tianqing Pharmaceutical Group, Antengene Corporation, Iterion Therapeutics, Sumitomo Pharma, SillaJen Biotherapeutics, SCG Cell Therapy, Guangdong ProCapZoom Biosciences, Eutilex, Polaris Pharmaceuticals, OriCell Therapeutics, Gongwin Biopharm, Celgene Corporation, Phanes Therapeutics, MacroGenics, Genoscience Pharma, Tempest Therapeutics, JW Therapeutics, NETRIS Pharma, Adagene, and others.
• Key Hepatocellular Carcinoma Pipeline Therapies: Namodenoson, Tivozanib, SCT-I10A, OBT-624, SynOV1.1, SRF388, INC280, HX008, AK104, Serplulimab, ERY974, Fisogatinib, Icaritin, TSR-022, TT-4, TTI-101, VG161, YIV-906, TQB2450, ATG 008, BBI608, Tegavivint, Pexastimogene Devacirepvec, SCG101, SZ003, EU307, ADI-PEG20, Ori-C101, Para-Toluenesulfonamide, CC-122, PT199, vobramitamab duocarmazine, ezurpimtrostat, TPST-1120, JWATM214, NP137, ADG126, and others.

 

Dive deep into rich insights for drugs used for Hepatocellular Carcinoma treatment; visit @ Hepatocellular Carcinoma Drugs 

 

Table of Contents

1.	Introduction
2.	Executive Summary
3.	Hepatocellular Carcinoma Pipeline: Overview
4.	Analytical Perspective In-depth Commercial Assessment
5.	Hepatocellular Carcinoma Pipeline Therapeutics
6.	Hepatocellular Carcinoma Pipeline: Late Stage Products (Phase III)
7.	Hepatocellular Carcinoma Pipeline: Late Stage Products (Phase III)
8.	Hepatocellular Carcinoma Pipeline: Mid-Stage Products (Phase II)
9.	Hepatocellular Carcinoma Pipeline: Early Stage Products (Phase  I)
10.	Hepatocellular Carcinoma Therapeutic Assessment
11.	Inactive Hepatocellular Carcinoma Products
12.	Company-University Collaborations (Licensing/Partnering) Analysis
13.	Key Hepatocellular Carcinoma Companies
14.	Key Hepatocellular Carcinoma Products
15.	Hepatocellular Carcinoma Unmet Needs
16.	Hepatocellular Carcinoma Market Drivers and Barriers
17.	Future Perspectives and Conclusion
18.	Analyst Views
19.	Appendix

 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting